Title |
Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases
|
---|---|
Published in |
Annals of Hematology, April 2010
|
DOI | 10.1007/s00277-010-0948-7 |
Pubmed ID | |
Authors |
Lina Han, Jan Jacob Schuringa, André Mulder, Edo Vellenga |
Abstract |
A number of signaling pathways might be frequently disrupted in acute myeloid leukemia (AML). We questioned whether the dual SRC/ABL kinase inhibitor dasatinib can affect AML cells and whether differences can be observed with normal CD34(+) cells. First, we demonstrated that normal cord blood (CB) CD34(+) cells were unaffected by dasatinib at a low concentration (0.5 nM) in the long-term culture on MS5 stromal cells. No changes were observed in proliferation, differentiation, and colony formation. In a subset of AML cases (3/15), a distinct reduction in cell proliferation was observed, ranging from 48% to 91% inhibition at 0.5 nM of dasatinib, in particular, those characterized by BCR-ABL or KIT mutations. Moreover, the inhibitory effects of dasatinib were cytokine specific. Stem cell factor-mediated proliferation was significantly impaired, associated with a reduced phosphorylation of ERK1/2 and STAT5, whereas no effect was observed on interleukin-3 and thrombopoietin-mediated signaling despite SRC activation. In conclusion, this study demonstrates that dasatinib is a potential inhibitor in a subgroup of AML, especially those that express BCR-ABL or KIT mutations. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 25% |
Student > Ph. D. Student | 6 | 25% |
Professor | 2 | 8% |
Student > Postgraduate | 2 | 8% |
Professor > Associate Professor | 2 | 8% |
Other | 3 | 13% |
Unknown | 3 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 6 | 25% |
Medicine and Dentistry | 5 | 21% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
Neuroscience | 3 | 13% |
Immunology and Microbiology | 1 | 4% |
Other | 3 | 13% |
Unknown | 3 | 13% |